Mankind Pharma’s Journey to Becoming a Leading Biotech Company

Mankind Pharma, a name synonymous with affordable healthcare, has steadily risen to prominence in the biotechnology sector. Known for its commitment to innovation and accessibility, the company has evolved into one of the best biotech companies in India. This blog explores Mankind Pharma’s journey, highlighting its strategic milestones, innovative capabilities, and future outlook.

The Genesis of Mankind Pharma

Founded in 1991 by Ramesh C. Juneja and Rajeev Juneja, Mankind Pharma began its operations in 1995 with a vision to provide high-quality medicines at affordable prices. Over the years, it has grown into India’s fourth-largest pharmaceutical company by value and volume, with a revenue of ₹10,335 crore in FY 2023-24. Initially focused on pharmaceuticals and consumer healthcare products, Mankind Pharma has diversified into biotechnology to address critical healthcare challenges.

Strategic Entry into Biotechnology

Biotechnology, which leverages living cells to develop advanced therapies, has become a cornerstone of modern medicine. Recognizing its potential, Mankind Pharma entered this domain with a focus on biosimilars – biologically similar versions of complex biologic drugs. The company’s biotechnology division specializes in oncology, chronic inflammatory diseases, and metabolic disorders.

Key Capabilities in Biotechnology

Mankind Pharma’s state-of-the-art R&D infrastructure is central to its biotechnology initiatives. The company employs cutting-edge techniques such as:

• Molecular biology and genetic engineering
• Protein isolation and purification
• Cell culture scale-up and fermentation
• Single-cell cloning and cell banking

These capabilities enable the development of high-quality biosimilars that are both effective and affordable.

Acquisition of Bharat Serums & Vaccines

A pivotal moment in Mankind Pharma’s biotech journey was its acquisition of Bharat Serums & Vaccines (BSV) in 2024. This strategic move expanded Mankind’s portfolio into high-entry-barrier segments like women’s health, fertility drugs, and critical care products. BSV, established in 1971, is renowned for its expertise in biological and biotech formulations. The acquisition not only strengthened Mankind’s domestic operations but also positioned it as a leader in niche therapeutic areas.

Innovative Products and Research

Mankind Pharma’s commitment to innovation is evident in its robust pipeline of products. In addition to biosimilars, the company is exploring new drug discovery through its New Drug Discovery and Research (NDDR) department. 

Global Collaborations

Mankind Pharma’s global partnerships have further bolstered its biotech capabilities. In 2023, the company signed a licensing agreement with Innovent Biologics to commercialize Sintilimab—a monoclonal antibody used in oncology—in India. This collaboration underscores Mankind’s commitment to bringing advanced therapies to Indian patients at affordable prices. The company has also entered into in-licensing agreements with global pharmaceutical giants such as AstraZeneca, Novartis, and Takeda. These collaborations have facilitated the introduction of advanced therapies in the Indian market, thereby broadening Mankind Pharma’s biotechnology portfolio and reinforcing its commitment to providing cutting-edge healthcare solutions.

Manufacturing Excellence

Mankind Pharma operates 21 manufacturing facilities across India that adhere to stringent cGMP and FDA guidelines. These facilities are equipped with advanced technologies for producing sterile preparations, multilayer tablets, nano-emulsion ophthalmics, and more. The integration of Bharat Serums & Vaccines’ manufacturing capabilities has further enhanced Mankind’s production efficiency.

Market Leadership

Mankind Pharma’s focus on affordability has made it a household name in India. It ranks #1 in prescription volume for seven consecutive years and #4 by value. The acquisition of BSV is expected to solidify its leadership position by adding high-margin biotech products to its portfolio.

Commitment to Accessibility

One of the defining aspects of Mankind Pharma’s strategy is its emphasis on accessibility. By leveraging economies of scale and innovative processes, the company ensures that advanced therapies are within reach for patients across urban and rural areas.

Future Outlook

Mankind Pharma is well-positioned to capitalize on the growing demand for biotech solutions. According to industry reports, the global biotechnology market is expected to grow at a CAGR of 13.96% between 2024 and 2030. With its strong R&D foundation, strategic acquisitions like BSV, and global collaborations, Mankind Pharma aims to be at the forefront of this growth.

Key Growth Drivers

• Expansion into international markets through subsidiaries in the U.S. and Singapore.
• Continued investment in R&D; Mankind Pharma’s 660 scientists are dedicated to developing cost-effective solutions.
• Focus on high-growth therapeutic areas like oncology and metabolic disorders.

Mankind Pharma’s journey from a pharmaceutical company to one of the best biotech companies exemplifies strategic vision and relentless innovation. Through investments in R&D infrastructure, acquisitions like Bharat Serums & Vaccines, and global collaborations, the company has carved a niche for itself in the biotechnology sector. As it continues to expand its horizons, Mankind Pharma remains committed to enabling healthier lives through affordable and accessible healthcare solutions.

With its strong foundation and forward-looking strategies, Mankind Pharma is not just shaping its future but also contributing significantly to India’s position as a global leader in biotechnology.

Image Source: Freepik